DNLI
Price
$15.43
Change
+$0.64 (+4.33%)
Updated
Sep 5 closing price
Capitalization
2.26B
54 days until earnings call
FENC
Price
$9.00
Change
-$0.18 (-1.96%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
250.18M
61 days until earnings call
Interact to see
Advertisement

DNLI vs FENC

Header iconDNLI vs FENC Comparison
Open Charts DNLI vs FENCBanner chart's image
Denali Therapeutics
Price$15.43
Change+$0.64 (+4.33%)
Volume$4.19M
Capitalization2.26B
Fennec Pharmaceuticals
Price$9.00
Change-$0.18 (-1.96%)
Volume$354
Capitalization250.18M
DNLI vs FENC Comparison Chart in %
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. FENC commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a StrongBuy and FENC is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (DNLI: $15.43 vs. FENC: $9.00)
Brand notoriety: DNLI and FENC are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 237% vs. FENC: 91%
Market capitalization -- DNLI: $2.26B vs. FENC: $250.18M
DNLI [@Biotechnology] is valued at $2.26B. FENC’s [@Biotechnology] market capitalization is $250.18M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileFENC’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • FENC’s FA Score: 0 green, 5 red.
According to our system of comparison, FENC is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 4 TA indicator(s) are bullish while FENC’s TA Score has 6 bullish TA indicator(s).

  • DNLI’s TA Score: 4 bullish, 5 bearish.
  • FENC’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, FENC is a better buy in the short-term than DNLI.

Price Growth

DNLI (@Biotechnology) experienced а +1.05% price change this week, while FENC (@Biotechnology) price change was +1.47% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.52%, and the average quarterly price growth was +33.01%.

Reported Earning Dates

DNLI is expected to report earnings on Oct 30, 2025.

FENC is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DNLI($2.26B) has a higher market cap than FENC($250M). FENC YTD gains are higher at: 45.253 vs. DNLI (-24.289). FENC has higher annual earnings (EBITDA): -8.39M vs. DNLI (-521.52M). DNLI has more cash in the bank: 899M vs. FENC (18.7M). FENC has less debt than DNLI: FENC (19.4M) vs DNLI (46.6M). FENC has higher revenues than DNLI: FENC (33.3M) vs DNLI (0).
DNLIFENCDNLI / FENC
Capitalization2.26B250M902%
EBITDA-521.52M-8.39M6,214%
Gain YTD-24.28945.253-54%
P/E RatioN/A60.43-
Revenue033.3M-
Total Cash899M18.7M4,807%
Total Debt46.6M19.4M240%
FUNDAMENTALS RATINGS
DNLI vs FENC: Fundamental Ratings
DNLI
FENC
OUTLOOK RATING
1..100
116
VALUATION
overvalued / fair valued / undervalued
1..100
93
Overvalued
88
Overvalued
PROFIT vs RISK RATING
1..100
10092
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
6243
P/E GROWTH RATING
1..100
9998
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FENC's Valuation (88) in the Biotechnology industry is in the same range as DNLI (93). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

FENC's Profit vs Risk Rating (92) in the Biotechnology industry is in the same range as DNLI (100). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

DNLI's SMR Rating (97) in the Biotechnology industry is in the same range as FENC (100). This means that DNLI’s stock grew similarly to FENC’s over the last 12 months.

FENC's Price Growth Rating (43) in the Biotechnology industry is in the same range as DNLI (62). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

FENC's P/E Growth Rating (98) in the Biotechnology industry is in the same range as DNLI (99). This means that FENC’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLIFENC
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 2 days ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
69%
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 2 days ago
78%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 2 days ago
81%
Advances
ODDS (%)
Bullish Trend 9 days ago
77%
Bullish Trend 10 days ago
76%
Declines
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 18 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
Bearish Trend 2 days ago
81%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 2 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
FENC
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EDDRF9.00N/A
N/A
EDreams Odigeo SA
SHLRF343.00N/A
N/A
Schindler Holding AG
USSJY23.92N/A
N/A
USS Co. Ltd.
STBK11.48N/A
N/A
Studio Financial Holdings, Inc.
ZUUZF0.10N/A
-0.10%
Zeus North America Mining Corp.

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with NRIX. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then NRIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+4.33%
NRIX - DNLI
58%
Loosely correlated
+8.66%
BEAM - DNLI
55%
Loosely correlated
+12.62%
OCUL - DNLI
54%
Loosely correlated
+7.09%
RGNX - DNLI
53%
Loosely correlated
+3.08%
IDYA - DNLI
52%
Loosely correlated
+5.15%
More

FENC and

Correlation & Price change

A.I.dvisor indicates that over the last year, FENC has been loosely correlated with IDYA. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if FENC jumps, then IDYA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To FENC
1D Price
Change %
FENC100%
+3.61%
IDYA - FENC
46%
Loosely correlated
+0.27%
CLDX - FENC
44%
Loosely correlated
-3.52%
BEAM - FENC
43%
Loosely correlated
-1.17%
DNLI - FENC
43%
Loosely correlated
-3.40%
CGEM - FENC
41%
Loosely correlated
-10.49%
More